Response Genetics, Inc, a company focusing on the development and sale of molecular diagnostic tests for cancer, has signed a non-exclusive license agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumour samples. Payments will be made to Response Genetics upon achievement of agreed-to milestones. Further financial details were not disclosed.

The BRAF gene encodes B-Raf proto-oncogene serine/threonine-protein kinase (B-raf), a protein involved in cell signaling and cellular growth and differentiation. Specific genetic mutations have been correlated with the development of certain forms of cancer.

"As a provider of genetic testing services to GSK, we are pleased to continue to support GSK's clinical trial program," said Kathleen Danenberg, president and CEO of Response Genetics. "Through access to our proprietary technology, Response Genetics provides pharmaceutical companies with unique information and insights. By identifying specific genetic mutations, such as in the BRAF gene, we hope to enable the development of diagnosis tools for disease prognosis that may aid in treatment decisions."

Response Genetics' holds other patented diagnostic technology and provides services to physicians through the company's ResponseDX series of tests - proprietary PCR-based tests used to analyze the expression of genes that correlate with response to commonly used chemotherapy agents.

Response Genetics is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies.